This Pharma Stock Is Down 19% In 2025 But Just Received An 'Explosive News' Find Out More

2025-08-28 03:14:14

(MENAFN- AsiaNet News)

Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced on Thursday that the U.S. Food and Drug Administration has approved a generic version of the Liraglutide injection known as Saxenda.

Liraglutide Injection is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated to reduce excess body weight and maintain weight reduction long-term in adults as well as pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. The drug is to be used in combination with a reduced-calorie diet and increased physical activity.

“With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss,” said Ernie Richardsen, Head of U.S. Commercial Generics at Teva. He added that it marks an important addition to the company's generics portfolio.

Saxenda, Novo Nordisk's older obesity drug, had annual sales of $165 million as of June 2025, the company said. On Stocktwits, retail sentiment around TEVA stock trended within 'neutral' territory over the past 24 hours, while message volume remained at 'high' levels.

TEVA's Sentiment Meter and Message Volume as of 9:52 a.m. ET on Aug. 28, 2025 | Source: Stocktwits

A Stocktwits user expressed surprise that the stock is not trading higher despite the approval.

Another user sounded skeptical, saying that the stock would probably end the day in the red despite“explosive news.”

In the second quarter, Teva recorded revenue of $4.2 billion and adjusted and diluted earnings per share of $0.66. Generics product revenues in the U.S., however, fell 6% to $961 million, due to lower revenues from Lenalidomide capsules, the generic version of Revlimid, and Liraglutide injection 1.8mg, an authorized generic of Victoza, primarily driven by increased competition.

TEVA stock is down 19% this year and approximately 3% over the past 12 months.

For updates and corrections, email newsroom[at]stocktwits[dot]com

MENAFN28082025007385015968ID1109990624

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.